Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice
- PMID: 17885736
- DOI: 10.1007/s10928-007-9072-2
Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice
Abstract
The objective of this study was to investigate the pharmacokinetics and toxicodynamics of topotecan (TPT) in mice and to develop an integrated pharmacokinetic/toxicodynamic (PK/TD) model to characterize the relationship between the time course of TPT disposition and the time course of TPT-induced toxicity. TPT was administered to groups of 3-5 mice via i.v. bolus injection, i.p. bolus injection, and by i.p. infusion over 24, 72 and 168 h. Body weight was monitored to assess TPT-induced toxicity, and serial blood samples were collected and analyzed via HPLC to assess TPT pharmacokinetics. We found that TPT-induced toxicity increased dose-dependently for each mode of dosing investigated. The time course of topotecan-induced body weight-loss was delayed relative to the time course of topotecan disposition; nadir body weight was observed as late as 6 days following i.p. bolus dosing, and 3-5 days following termination of i.p. infusion. TPT exhibited non-linear disposition, which was well-characterized through the use of a two-compartment model with saturable elimination from the central compartment. Toxicodynamic data were characterized with an integrated PK/TD model that incorporated an indirect-effect model and four transit compartments to describe transduction events associated with TPT-induced toxicity. This model will be used to support the development of an inverse-targeting strategy that aims to enhance topotecan safety and efficacy.
Similar articles
-
PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.Int J Pharm. 2014 Apr 25;465(1-2):228-38. doi: 10.1016/j.ijpharm.2014.01.038. Epub 2014 Feb 6. Int J Pharm. 2014. PMID: 24508555 Free PMC article.
-
Using plasma topotecan pharmacokinetics to estimate topotecan exposure in cerebrospinal fluid of children with medulloblastoma.Neuro Oncol. 2006 Apr;8(2):89-95. doi: 10.1215/15228517-2005-004. Epub 2006 Feb 3. Neuro Oncol. 2006. PMID: 16461424 Free PMC article. Clinical Trial.
-
High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.Ann Oncol. 1998 Feb;9(2):173-80. doi: 10.1023/a:1008266630701. Ann Oncol. 1998. PMID: 9553662 Clinical Trial.
-
Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.Cancer Chemother Pharmacol. 2000;46(3):204-10. doi: 10.1007/s002800000141. Cancer Chemother Pharmacol. 2000. PMID: 11021737 Clinical Trial.
-
The evolving role of oral topotecan.Semin Hematol. 1999 Oct;36(4 Suppl 8):26-32. Semin Hematol. 1999. PMID: 10622226 Review.
Cited by
-
Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy.Pharmaceutics. 2020 Feb 3;12(2):125. doi: 10.3390/pharmaceutics12020125. Pharmaceutics. 2020. PMID: 32028733 Free PMC article.
-
PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.Int J Pharm. 2014 Apr 25;465(1-2):228-38. doi: 10.1016/j.ijpharm.2014.01.038. Epub 2014 Feb 6. Int J Pharm. 2014. PMID: 24508555 Free PMC article.
-
Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy.J Pharmacol Exp Ther. 2009 May;329(2):580-91. doi: 10.1124/jpet.108.149443. Epub 2009 Feb 20. J Pharmacol Exp Ther. 2009. PMID: 19233938 Free PMC article.
-
Physiologically based pharmacokinetic model for topotecan in mice.J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):121-42. doi: 10.1007/s10928-010-9181-1. Epub 2010 Nov 20. J Pharmacokinet Pharmacodyn. 2011. PMID: 21104004
-
Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):707-718. doi: 10.1007/s13318-016-0389-3. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27889876
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources